Matches in UGent Biblio for { <https://biblio.ugent.be/publication/5672255#aggregation> ?p ?o. }
Showing items 1 to 46 of
46
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B1030632.
- aggregation creator B1030633.
- aggregation creator B1030634.
- aggregation creator B1030635.
- aggregation creator B1030636.
- aggregation creator B1030637.
- aggregation creator B1030638.
- aggregation creator B1030639.
- aggregation creator B1030640.
- aggregation creator B1030641.
- aggregation creator B1030642.
- aggregation creator B1030643.
- aggregation creator B1030644.
- aggregation creator B1030645.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 5672255.bibtex.
- aggregation hasFormat 5672255.csv.
- aggregation hasFormat 5672255.dc.
- aggregation hasFormat 5672255.didl.
- aggregation hasFormat 5672255.doc.
- aggregation hasFormat 5672255.json.
- aggregation hasFormat 5672255.mets.
- aggregation hasFormat 5672255.mods.
- aggregation hasFormat 5672255.rdf.
- aggregation hasFormat 5672255.ris.
- aggregation hasFormat 5672255.txt.
- aggregation hasFormat 5672255.xls.
- aggregation hasFormat 5672255.yaml.
- aggregation isPartOf urn:issn:1094-6950.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis".
- aggregation abstract "FREEDOM was a phase 3 trial in 7808 women aged 60-90 yr with postmenopausal osteoporosis. Subjects received placebo or 60 mg denosumab subcutaneously every 6 mo for 3 yr in addition to daily calcium and vitamin D. Denosumab significantly decreased bone turnover; increased dual-energy X-ray absorptiometry (DXA) areal bone mineral density (aBMD); and significantly reduced new vertebral, nonvertebral, and hip fractures. In a subset of women (N = 209), lumbar spine, total hip, and femoral neck volumetric BMD (vBMD) were assessed by quantitative computed tomography at baseline and months 12, 24, and 36. Significant improvement from placebo and baseline was observed in aBMD and vBMD in the denosumab-treated subjects at all sites and time points measured. The vBMD difference from placebo reached 21.8%, 7.8%, and 5.9%, respectively, for the lumbar spine, total hip, and femoral neck at 36 mo (all p < 0.0001). Compared with placebo and baseline, significant increases were also observed in bone mineral content (BMC) at the total hip (p < 0.0001) largely related to significant BMC improvement in the cortical compartment (p < 0.0001). These results supplement the data from DXA on the positive effect of denosumab on BMD in both the cortical and trabecular compartments.".
- aggregation authorList BK1445420.
- aggregation endPage "256".
- aggregation issue "2".
- aggregation startPage "250".
- aggregation volume "16".
- aggregation aggregates 5672382.
- aggregation isDescribedBy 5672255.
- aggregation similarTo j.jocd.2012.02.014.
- aggregation similarTo LU-5672255.